Share This Article:

Cure for Alzheimer’s Disease

Full-Text HTML XML Download Download as PDF (Size:208KB) PP. 328-330
DOI: 10.4236/wjns.2015.55030    4,009 Downloads   4,467 Views   Citations
Author(s)    Leave a comment

ABSTRACT

Alzheimer’s disease (AD) is progressively being recognized amongst the most vital medical and social issues in older individuals in industrialized and non-industrialized countries. To date, just symptomatic medications exist for this disease, all attempting to offset the neurotransmitter disturbance. Recently, cholinesterase inhibitors (CIs) are now accessible and have been authorized for the treatment of mild to moderate AD. Further remedial alternative available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments equipped for halting or slightly adjusting the course of AD are known as “ailment changing” medications, and are still under extensive examination. To obstruct the movement of the ailment, they need to interfere with the pathogenic steps in charge of the clinical symptoms, including the disposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, irritation, oxidative damage, iron deregulation and cholesterol metabolism. This paper discusses the cure for Alzheimer’s disease, the current symptomatic treatments and the treatment of mild and moderate Alzheimer’s disease and the functions of its drugs.

Cite this paper

Patnaik, N. (2015) Cure for Alzheimer’s Disease. World Journal of Neuroscience, 5, 328-330. doi: 10.4236/wjns.2015.55030.

References

[1] Ferri, C., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., et al. (2005) Global Prevalence of Dementia: A Delphi Consensus Study. Lancet, 366, 2112-2117.
http://dx.doi.org/10.1016/S0140-6736(05)67889-0
[2] Lansdall, C.J. (2014) An Effective Treatment for Alzheimer’s Disease Must Consider both Amyloid and Tau. Bioscience Horizons, 7, 1-11. http://dx.doi.org/10.1093/biohorizons/hzu002
[3] Hort, J., O’Brien, J.T., Gainotti, G., Pirttila, T., Popescu, B.O., Rektorova, I., et al. (2010) EFNS Guidelines for the Diagnosis and Management of Alzheimer’s Disease. European Journal of Neurology, 17, 1236-1248. http://dx.doi.org/10.1111/j.1468-1331.2010.03040.x
[4] Yang, H.Q., Sun, Z.K. and Chen, S.D. (2012) Current Advances in the Treatment of Alzheimer’s Disease: Focused on Considerations Targeting Aβ and Tau. Transnational Neurodegeneration, 1, 1-12.
[5] Alzheimer’s Association (2012) FDA: Approved Treatments for Alzheimer’s.
https://www.alz.org/national/documents/topicsheet_treatments.pdf
[6] Alzheimer’s Disease Education and Referral Center (2008) Alzheimer’s Disease Medications. National Institute of Aging.
https://www.nia.nih.gov/sites/default/files/ad_meds_fact_sheet-2014_update-final_2-12-14.pdf
[7] Aprahamian, I., Stella, F. and Forlenza, O.V. (2013) New Treatment Strategies for Alzheimer’s Disease: Is There Hope? Indian Journal of Medical Research, 138, 449-460.

  
comments powered by Disqus

Copyright © 2017 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.